The FDA has granted approval for a higher dose version of the weight-loss medication Wegovy, also known as semaglutide, under the National Priority Voucher Program. This new formulation is designed to enhance weight loss results, showing an average weight reduction of 21% in clinical trials. Novo Nordisk aims to reclaim market share with this approval, as the landscape for obesity treatments shifts with competition from both injectables and emerging oral medications. As sales forecasts for injectable weight-loss drugs plateau, the focus is increasingly turning towards pill-based treatments, positioning the higher-dose Wegovy as a potential frontrunner in the ongoing battle for weight-loss supremacy.